Cargando…

Impact of extending direct antiviral agents (DAA) availability in France: an observational cohort study (2015-2019) of data from French administrative healthcare databases (SNDS).

BACKGROUND: Direct antiviral agents (DAAs) became available in France in 2014 for the treatment of chronic hepatitis C (CHC) in patients with severe fibrosis (prioritized access); in 2017, DAAs became available to all CHC patients (universal access). We evaluated the impact of extending DAA availabi...

Descripción completa

Detalles Bibliográficos
Autores principales: Pol, Stanislas, Fouad, Fayssoil, Lemaitre, Magali, Rodriguez, Ingrid, Lada, Olivier, Rabiega, Pascaline, Benabadji, Elias, Roudot-Thoraval, Françoise
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8671622/
https://www.ncbi.nlm.nih.gov/pubmed/34950924
http://dx.doi.org/10.1016/j.lanepe.2021.100281
_version_ 1784615176305115136
author Pol, Stanislas
Fouad, Fayssoil
Lemaitre, Magali
Rodriguez, Ingrid
Lada, Olivier
Rabiega, Pascaline
Benabadji, Elias
Roudot-Thoraval, Françoise
author_facet Pol, Stanislas
Fouad, Fayssoil
Lemaitre, Magali
Rodriguez, Ingrid
Lada, Olivier
Rabiega, Pascaline
Benabadji, Elias
Roudot-Thoraval, Françoise
author_sort Pol, Stanislas
collection PubMed
description BACKGROUND: Direct antiviral agents (DAAs) became available in France in 2014 for the treatment of chronic hepatitis C (CHC) in patients with severe fibrosis (prioritized access); in 2017, DAAs became available to all CHC patients (universal access). We evaluated the impact of extending DAA availability on CHC patient care, especially on screening and time to treatment. METHODS: Adult patients affiliated with the national health insurance system (SNDS) who were screened or treated for CHC between 2015 and 2019 were included. Algorithms were developed to identify at-risk subpopulations. FINDINGS: The proportion of screened patients increased by 1% between 2015 and 2019, from 4·6% to 5·6%. The main nonexclusive risk factors for CHC were psychiatric conditions (27%), drug use (21%) and HIV positivity (11%); more than 50% of psychiatric patients had additional risk factors, mainly drug use with a 38% to 52% overlap. The median interval between the last screening test and treatment initiation decreased from 64 days in 2015 to 37 days in 2019. During the study period, 71,466 patients began CHC treatment (median age 55 [48-62]; 59% male), including 46% of “at-risk” patients with an increase in treatment initiation by 44% between 2015 and 2017 and a decrease of 46% between 2017 and 2019. Only 2,212 (3%) patients were treated at least twice. Among treated patients, the proportion of HIV+ patients decreased from 19% to 8% (prioritization consequence), while the proportions increased in the other at-risk subpopulations. INTERPRETATION: we showed that policies extending DAA availability are associated with a screening increase and a decrease in the time to treatment initiation, while universal access led to a surge in treatment initiations in 2017. This study may also contribute to improving the cascade of care in the at-risk subpopulations. For instance, by pointing out their relative importance, especially for the psychiatric subpopulation, it highlights the importance to address them with tailored policies.
format Online
Article
Text
id pubmed-8671622
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-86716222021-12-22 Impact of extending direct antiviral agents (DAA) availability in France: an observational cohort study (2015-2019) of data from French administrative healthcare databases (SNDS). Pol, Stanislas Fouad, Fayssoil Lemaitre, Magali Rodriguez, Ingrid Lada, Olivier Rabiega, Pascaline Benabadji, Elias Roudot-Thoraval, Françoise Lancet Reg Health Eur Article BACKGROUND: Direct antiviral agents (DAAs) became available in France in 2014 for the treatment of chronic hepatitis C (CHC) in patients with severe fibrosis (prioritized access); in 2017, DAAs became available to all CHC patients (universal access). We evaluated the impact of extending DAA availability on CHC patient care, especially on screening and time to treatment. METHODS: Adult patients affiliated with the national health insurance system (SNDS) who were screened or treated for CHC between 2015 and 2019 were included. Algorithms were developed to identify at-risk subpopulations. FINDINGS: The proportion of screened patients increased by 1% between 2015 and 2019, from 4·6% to 5·6%. The main nonexclusive risk factors for CHC were psychiatric conditions (27%), drug use (21%) and HIV positivity (11%); more than 50% of psychiatric patients had additional risk factors, mainly drug use with a 38% to 52% overlap. The median interval between the last screening test and treatment initiation decreased from 64 days in 2015 to 37 days in 2019. During the study period, 71,466 patients began CHC treatment (median age 55 [48-62]; 59% male), including 46% of “at-risk” patients with an increase in treatment initiation by 44% between 2015 and 2017 and a decrease of 46% between 2017 and 2019. Only 2,212 (3%) patients were treated at least twice. Among treated patients, the proportion of HIV+ patients decreased from 19% to 8% (prioritization consequence), while the proportions increased in the other at-risk subpopulations. INTERPRETATION: we showed that policies extending DAA availability are associated with a screening increase and a decrease in the time to treatment initiation, while universal access led to a surge in treatment initiations in 2017. This study may also contribute to improving the cascade of care in the at-risk subpopulations. For instance, by pointing out their relative importance, especially for the psychiatric subpopulation, it highlights the importance to address them with tailored policies. Elsevier 2021-12-11 /pmc/articles/PMC8671622/ /pubmed/34950924 http://dx.doi.org/10.1016/j.lanepe.2021.100281 Text en © 2021 The Author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Pol, Stanislas
Fouad, Fayssoil
Lemaitre, Magali
Rodriguez, Ingrid
Lada, Olivier
Rabiega, Pascaline
Benabadji, Elias
Roudot-Thoraval, Françoise
Impact of extending direct antiviral agents (DAA) availability in France: an observational cohort study (2015-2019) of data from French administrative healthcare databases (SNDS).
title Impact of extending direct antiviral agents (DAA) availability in France: an observational cohort study (2015-2019) of data from French administrative healthcare databases (SNDS).
title_full Impact of extending direct antiviral agents (DAA) availability in France: an observational cohort study (2015-2019) of data from French administrative healthcare databases (SNDS).
title_fullStr Impact of extending direct antiviral agents (DAA) availability in France: an observational cohort study (2015-2019) of data from French administrative healthcare databases (SNDS).
title_full_unstemmed Impact of extending direct antiviral agents (DAA) availability in France: an observational cohort study (2015-2019) of data from French administrative healthcare databases (SNDS).
title_short Impact of extending direct antiviral agents (DAA) availability in France: an observational cohort study (2015-2019) of data from French administrative healthcare databases (SNDS).
title_sort impact of extending direct antiviral agents (daa) availability in france: an observational cohort study (2015-2019) of data from french administrative healthcare databases (snds).
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8671622/
https://www.ncbi.nlm.nih.gov/pubmed/34950924
http://dx.doi.org/10.1016/j.lanepe.2021.100281
work_keys_str_mv AT polstanislas impactofextendingdirectantiviralagentsdaaavailabilityinfranceanobservationalcohortstudy20152019ofdatafromfrenchadministrativehealthcaredatabasessnds
AT fouadfayssoil impactofextendingdirectantiviralagentsdaaavailabilityinfranceanobservationalcohortstudy20152019ofdatafromfrenchadministrativehealthcaredatabasessnds
AT lemaitremagali impactofextendingdirectantiviralagentsdaaavailabilityinfranceanobservationalcohortstudy20152019ofdatafromfrenchadministrativehealthcaredatabasessnds
AT rodriguezingrid impactofextendingdirectantiviralagentsdaaavailabilityinfranceanobservationalcohortstudy20152019ofdatafromfrenchadministrativehealthcaredatabasessnds
AT ladaolivier impactofextendingdirectantiviralagentsdaaavailabilityinfranceanobservationalcohortstudy20152019ofdatafromfrenchadministrativehealthcaredatabasessnds
AT rabiegapascaline impactofextendingdirectantiviralagentsdaaavailabilityinfranceanobservationalcohortstudy20152019ofdatafromfrenchadministrativehealthcaredatabasessnds
AT benabadjielias impactofextendingdirectantiviralagentsdaaavailabilityinfranceanobservationalcohortstudy20152019ofdatafromfrenchadministrativehealthcaredatabasessnds
AT roudotthoravalfrancoise impactofextendingdirectantiviralagentsdaaavailabilityinfranceanobservationalcohortstudy20152019ofdatafromfrenchadministrativehealthcaredatabasessnds